Abstract
583P RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have